Lisanti Capital Growth LLC Sells 12,611 Shares of ANI Pharmaceuticals, Inc. $ANIP

Lisanti Capital Growth LLC cut its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 13.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 82,554 shares of the specialty pharmaceutical company’s stock after selling 12,611 shares during the quarter. ANI Pharmaceuticals comprises 1.8% of Lisanti Capital Growth LLC’s investment portfolio, making the stock its 5th largest holding. Lisanti Capital Growth LLC’s holdings in ANI Pharmaceuticals were worth $7,562,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ANIP. Assenagon Asset Management S.A. raised its holdings in ANI Pharmaceuticals by 259.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 46,328 shares of the specialty pharmaceutical company’s stock valued at $4,244,000 after acquiring an additional 33,438 shares in the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of ANI Pharmaceuticals during the third quarter valued at approximately $1,597,000. Intech Investment Management LLC raised its stake in shares of ANI Pharmaceuticals by 134.7% in the second quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company’s stock valued at $1,756,000 after purchasing an additional 15,447 shares in the last quarter. Decker Retirement Planning Inc. lifted its position in ANI Pharmaceuticals by 76,862.5% in the third quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after purchasing an additional 36,894 shares during the period. Finally, Squarepoint Ops LLC bought a new position in ANI Pharmaceuticals in the second quarter worth $2,137,000. 76.05% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Tuesday, January 13th. The shares were sold at an average price of $84.33, for a total transaction of $42,165.00. Following the transaction, the vice president owned 74,374 shares in the company, valued at $6,271,959.42. This represents a 0.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Renee P. Tannenbaum sold 1,800 shares of the stock in a transaction dated Friday, December 5th. The stock was sold at an average price of $81.15, for a total transaction of $146,070.00. Following the sale, the director directly owned 25,157 shares in the company, valued at approximately $2,041,490.55. This represents a 6.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 28,101 shares of company stock valued at $2,453,063 over the last three months. Company insiders own 11.10% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.2%

Shares of ANIP opened at $81.85 on Friday. The company has a market capitalization of $1.84 billion, a P/E ratio of 50.21 and a beta of 0.51. ANI Pharmaceuticals, Inc. has a one year low of $54.10 and a one year high of $99.50. The business’s 50 day simple moving average is $81.90 and its 200-day simple moving average is $84.94. The company has a debt-to-equity ratio of 1.20, a current ratio of 2.58 and a quick ratio of 2.04.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.74 by $0.30. The firm had revenue of $227.81 million during the quarter, compared to analysts’ expectations of $211.92 million. ANI Pharmaceuticals had a return on equity of 26.73% and a net margin of 4.91%.The business’s revenue was up 53.6% on a year-over-year basis. During the same period last year, the firm posted $1.34 EPS. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. As a group, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on ANIP shares. Weiss Ratings reissued a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Guggenheim upped their price objective on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research note on Friday, January 16th. Truist Financial raised their target price on ANI Pharmaceuticals from $77.00 to $90.00 and gave the stock a “hold” rating in a research report on Thursday, October 9th. Finally, Barclays initiated coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $100.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $103.43.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.